BG Medicine (BGMD) Getting Favorable Press Coverage, Accern Reports
News stories about BG Medicine (NASDAQ:BGMD) have been trending positive on Friday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BG Medicine earned a news sentiment score of 0.34 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 45.6500822473681 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of BG Medicine (NASDAQ BGMD) traded down 9.962% during midday trading on Friday, reaching $0.047. 4,195 shares of the company’s stock traded hands. The stock has a 50 day moving average of $0.05 and a 200-day moving average of $0.07. The stock’s market cap is $531993.00. BG Medicine has a 12 month low of $0.03 and a 12 month high of $0.22.
COPYRIGHT VIOLATION WARNING: “BG Medicine (BGMD) Getting Favorable Press Coverage, Accern Reports” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/07/21/bg-medicine-bgmd-getting-favorable-press-coverage-accern-reports.html.
BG Medicine Company Profile
BG Medicine, Inc (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company’s BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation.
Receive News & Ratings for BG Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BG Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.